BioNTech SE (BNTX) Intrinsic Value & DCF Valuation

Biotechnology · NASDAQ

Current Price

$80.96

Intrinsic Value

Use the calculator below to estimate

AI MOAT & RISK ANALYSIS
AI Generated · For Reference OnlyBNTX

COMPETITIVE MOAT

↑mRNA Technology Leadership

BioNTech possesses a leading position in mRNA technology, a platform with broad therapeutic potential beyond vaccines. This expertise creates a significant barrier to entry for competitors seeking to replicate their advanced capabilities.

↑Oncology Pipeline Expansion

The company is aggressively pivoting its mRNA platform towards a deep pipeline of oncology treatments. This strategic diversification aims to reduce reliance on COVID-19 vaccines and capture future growth in a high-demand area.

↑Strategic Partnerships

BioNTech has established key partnerships, such as with Pfizer for COVID-19 vaccines. These collaborations provide access to resources, distribution channels, and validation, strengthening its market position.

INVESTMENT RISKS

↓Regulatory Hurdles and Approval Delays

The development and approval of novel therapeutics, especially in oncology, are subject to stringent regulatory processes. Delays or rejections can significantly impact BioNTech's revenue and growth prospects.

↓Dependence on Future Pipeline Success

While diversifying, BioNTech's future growth is heavily dependent on the successful development and commercialization of its new pipeline candidates. Failure in these ventures poses a substantial risk.

↓Cash Flow and Profitability Concerns

Negative cash flow and concerns about profitability, as noted in recent analyses, indicate potential financial strain. This could limit investment in R&D and expansion, impacting long-term competitiveness.

This company has negative free cash flow, so a DCF model may not be suitable — it values future cash generation. You can still use the calculator below with your own assumptions.

Customize the BNTX valuation

Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for BioNTech SE respond.

Open DCF Calculator for BNTX

Or try PE Ratio Valuation for BNTX →

Company Overview

BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.

Financial Metrics — BNTX Stock Valuation Data

Revenue/Share (TTM)

$9.68

FCF/Share (TTM)

$-1.88

ROIC (TTM)

-8.3%

ROE (TTM)

-8.1%

P/FCF

n/m

EV/EBITDA

-19.3x

FCF Yield

-2.59%

Debt/Equity

0.02x

BNTX currently has negative free cash flow, so cash-flow ratios such as P/FCF and FCF yield do not give a meaningful read on whether the stock is cheap or expensive. A DCF valuation is unreliable until cash generation turns positive — focus on the path to profitability instead.

Frequently Asked Questions

What is the intrinsic value of BNTX?

BioNTech SE currently generates $-1.88 in free cash flow per share. At the current price of $80.96, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.

Is BNTX undervalued?

BNTX currently has negative free cash flow, so its P/FCF ratio is not meaningful and cannot tell you whether the stock is cheap or expensive. With cash flow negative, a DCF-based undervalued or overvalued judgment is unreliable — look at the path back to positive cash generation instead.

How do I value BNTX stock using DCF?

To perform a DCF valuation on BioNTech SE: (1) Start with the trailing free cash flow per share ($-1.88) as the base, (2) project future FCF growth over 5-10 years based on Biotechnology industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting BNTX's risk profile — with a debt-to-equity of 0.02x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.

What is DCF valuation and how does it apply to BNTX?

DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For BioNTech SE, this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Biotechnology trends, then discounting those amounts to today's dollars. BNTX's ROIC of -8.3% means the company's return on invested capital sits below the level that typically clears its cost of capital.

How does WACC affect BNTX stock valuation?

WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For BNTX, with a debt-to-equity ratio of 0.02x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of -19.3x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.

Learn More

Related Valuations

All Healthcare valuations

DCF and P/E value BNTX with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.

Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.

This is an estimate, not investment advice.